---
title: "Mabwell reshapes senior leadership to bolster pharma growth and governance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290218368.md"
description: "Mabwell (Shanghai) Bioscience Co., Ltd. (HK:2493) has overhauled its senior management team to bolster pharma growth and governance. Chairman Dr. Liu Datao was appointed general manager, alongside new deputy general managers, a CFO, and board secretary. The leadership changes, effective until the end of the third board session, aim to strengthen R&D, global expansion, and corporate stability by leveraging executives with deep scientific and financial expertise."
datetime: "2026-06-18T14:44:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290218368.md)
  - [en](https://longbridge.com/en/news/290218368.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290218368.md)
generator: "portal-rs"
---

# Mabwell reshapes senior leadership to bolster pharma growth and governance

Mabwell (Shanghai) Bioscience Co., Ltd. Class H ( (HK:2493) ) has provided an announcement.

Mabwell (Shanghai) Bioscience Co., Ltd. has overhauled its senior management team, appointing chairman Dr. Liu Datao as general manager and naming a slate of deputy general managers, along with a new chief financial officer and board secretary. The new leadership terms run from June 18, 2026 to the end of the board’s third session, consolidating operational control under an experienced cadre of pharma executives and signaling an emphasis on research-driven growth and corporate governance.

The appointments highlight the company’s push to strengthen research and development and global business expansion, with deputy general manager and R&D president Dr. Wu Hai bringing international experience from Stanford, Amgen and Chinese biotech firms. By elevating leaders with deep scientific and financial expertise, Mabwell aims to reinforce its competitive position in the biopharmaceutical sector and provide greater management stability for investors and other stakeholders.

**More about Mabwell (Shanghai) Bioscience Co., Ltd. Class H**

Mabwell (Shanghai) Bioscience Co., Ltd. is a PRC-based pharmaceutical and biopharmaceutical company listed in Hong Kong, focusing on drug research, development and commercialization. The company is led by experienced industry executives, including chairman and general manager Dr. Liu Datao, who has over two decades of R&D and management experience at major Chinese pharma groups and oversees the group’s overall strategic planning and operations.

**Average Trading Volume:** 1,813,419

**Current Market Cap:** HK$12.52B

### Related Stocks

- [02493.HK](https://longbridge.com/en/quote/02493.HK.md)

## Related News & Research

- [Mabwell Sets Board Meeting to Approve 2026 Interim Results](https://longbridge.com/en/news/296331890.md)
- [Mabwell Wins NMPA Nod to Test Novel Autoimmune Antibody 9MW5211 in Vitiligo](https://longbridge.com/en/news/292766513.md)
- [Yungjin Pharm Faces 9 Billion KRW Damage Claim in Seoul Court](https://longbridge.com/en/news/297623044.md)
- [BUZZ-Mid-cap drugmakers face limited impact from Trump drug pricing deals, analysts say](https://longbridge.com/en/news/297637201.md)
- [760,629 Shares in ACADIA Pharmaceuticals Inc. $ACAD Acquired by Bank of New York Mellon Corp](https://longbridge.com/en/news/297610061.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**